Aerpio Pharmaceuticals' Razuprotafib Dropped From Collaborative COVID-19 Trial

• Quantum Leap Healthcare Collaborative-sponsored I-SPY COVID Trial will not further test Aerpio Pharmaceuticals Inc's (NASDAQ: ARPO) razuprotafib.

• Razuprotafib was chosen because it was believed to stabilize and repair the lung's blood vessels and improve gas exchange.

• The I-SPY COVID Phase 2 Trial is an adaptive platform that is testing agents that promise to reduce the risk of death from and severity of illness after contracting COVID-19.

• Aerpio's razuprotafib will not be evaluated because it was challenging to administer in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension (low blood pressure).

• A small decline in systolic blood pressure and mean arterial blood pressure by approximately 4–5 mm Hg was observed after two safety lead-in cohorts.

• There was no indication that razuprotafib caused the hypotension that led to a clinical decline in systolic blood pressure.

• There was no significant difference between the 10 mg and 20 mg doses in blood pressure decline was seen.

• Blood pressure monitoring with additional scrutiny is challenging in the setting of a surge in ICU admissions from COVID-19. Hence, the Data Monitoring Committee recommended that razuprotafib not be advanced after the second safety lead-in.

• Price Action: ARPO shares are down 5.8% at $1.46 in premarket trading on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US

• Pfizer's Plant For Boosting COVID-19 Vaccine Production Has Been Rebuked For Repeat Quality Offenses: Bloomberg

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.